We report the complete genome sequence of a field isolate of a novel bipartite secovirid infecting cassava in Colombia, provisionally named "cassava torrado-like virus" (CsTLV). The genome sequence was obtained using Oxford Nanopore Technology, and the 5’ ends were confirmed by RACE. The RNA1 is 7252 nucleotides (nt) long, encoding a polyprotein of 2336 amino acids (aa) containing the typical “replication block”, conserved torradovirus motifs, and a Maf/Ham1 domain, which is not commonly found in viral genomes. The RNA2 is 4469 nt long and contains two overlapping ORFs encoding proteins of 226 and 1179 aa, showing the characteristic genome arrangement of members of the genus Torradovirus.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Cassava torrado-like virus (CsTLV) is a partially characterized member of the family Secoviridae [1, 2] that was originally detected in cassava plants (Manihot esculenta Crantz) displaying root symptoms of cassava frogskin disease (CFSD) [3], an endemic disease of cassava in the Americas that can severely affect the root yield of the crop [4]. The virus is found in mixed infections [3, 5] and can induce leaf chlorotic spots symptoms in single infections in cassava [2]. Maf/HAM1 proteins are nucleoside triphosphate (NTP) pyrophosphatases that reduce mutagenesis by intercepting non-canonical NTPs and preventing their incorporation into DNA or RNA. They are highly conserved in prokaryotes and eukaryotes [6], but there are only a couple of examples of their presence in viral genomes [7, 8].
The complete genome of CsTLV was obtained from a cassava plant of the commercial variety Melua-31, collected in August 2020 in Yopal, Colombia, and total RNA extraction with CTAB was done as reported previously [9]. For library preparation, we followed the SQK-DCS109 protocol (Oxford Nanopore Technologies), which uses RNase Cocktail Enzyme Mix (Thermo Fisher) to eliminate ribosomal RNA. The library was loaded onto a FLO-MIN106 R9.4 flowcell and sequenced for 48 h in a MinION using MinKnow software v2.0. Basecalling was performed using Guppy v5.0.11, and assembly was performed as described by Leiva et al. [10]. The quality of the consensus sequence obtained was checked using Qualimap v2.2.1 [11], and low-coverage regions and 5’ ends were confirmed by sequencing of overlapping RT-PCR products and using a 5' RACE System for Rapid Amplification of cDNA Ends (Invitrogen).
Anzeige
Excluding the poly-A tail, the RNA1 (OK040225) is 7252 nt long and has a single open reading frame encoding a polyprotein of 2336 aa (260 kDa). It contains the typical “replication block” and a Maf/Ham1 domain at its 3’ end at aa 2165 (Fig. 1A). The RNA2 (OK040226) is 4469 nt long and contains two ORFs: RNA2-ORF1 is 678 nt long and encodes a predicted protein of 226 aa (25 kDa). RNA2-ORF2 is 3534 nt long and overlaps with 44 nt of the 3’ end of RNA2-ORF1; it encodes a predicted polyprotein of 1179 aa (131 kDa) containing the 3A/RNA2 movement protein domain (A3) and three coat proteins domains. The sequence obtained showed more than 98% aa sequence identity to all other partial CsTLV sequences available in the GenBank database, and BLASTp analysis revealed the highest aa sequence identity to squash chlorotic leaf spot virus (NC_035221; NC_035222), with 37.75% aa sequence identity and 82% coverage for RNA1 and 45.53% sequence aa identity and 77% coverage for RNA2.
Fig. 1
(A) Genome organization of CsTLV isolate Yop12 showing the location of conserved consensus motifs shared by torradoviruses [1] and the Maf/Ham1 domain (red frame). (B) Phylogenetic relationships of CsTLV to members of the genus Torradovirus, analyzed using the aa sequences of RNA1 and RNA2 polyproteins. The phylogenetic tree was generated by the neighbor-joining method using MEGA. The evolutionary distances were computed using the Poisson correction method (number of aa substitutions per site).
×
Maf/Ham1 domains have only been reported in potyvirids. The first one was discovered by Mbanzibwa et al. [7] while working on the characterization of a Tanzanian isolate of cassava brown streak virus (genus Ipomovirus) (GenBank accession no. FJ039520.1), and a second one was reported by Knierim et al. [8] in a German isolate of euphorbia ringspot virus (genus Potyvirus) (GenBank accession no. NC_031339.1) (Fig. 2). Recently, Tomlinson et al. [12] demonstrated the activity of the potyvirid Maf/Ham1 in yeast and uncovered their role as a necrosis determinant in Nicotiana benthamiana, and James et al. [13] have suggested possible functions for this domain. In conclusion, CsTLV is an atypical secovirid encoding a Maf/Ham1 protein domain, which has been described so far only in viruses infecting euphorbiaceous hosts [2, 7, 8]. Further studies are underway to determine the biological role of CsTLV Maf/Ham1 in the virus infection cycle in cassava.
Fig. 2
(A) Sequence alignment showing the conserved sites of Maf/Ham1 domains from different taxa. The figure was made using Mview [14]. (B) Phylogenetic relationships of the Maf/Ham1 domain. Viruses (in red): EuRSV-PV-0902, YP_009305422; CBSV-Nampula, AYW01246; CBSV-Tan_Z, ACT78701; CBSV-Ug65, QGW67508; CBSV-CGCC-2017, QCR98745; UCBSV-Kikombe, ARQ80023; UCBSV-MLB3, ACM48176; UCBSV-Ug_23, CBA18486; UCBSV-Ke_125, ASG92173; CsTLV-Yop12, ??OK040225??; Escherichia 1K7K_A; Pseudomonas, WP_011064019; Burkholderia, KHS13049; Azoarcus, CAL96580; Rhizobium, CAK05869; Saccharomyces, CAA89597; Aspergillus, XP_754075; Neurospora, XP_955963; Arabidopsis, NP_567410; Oryza, XP_015613001; Manihot, XP_021594792; Caenorhabditis, AAL14111; Tetrahymena, XP_977249; Acyrthosiphon, NP_001233079; Drosophila, EDV32196; Culex, XP_038111262; Tribolium, XP_974197; Xenopus, AAI10772; Danio, NP_001093456; Mus, EDL28288; Homo, AAK21848
×
Acknowledgements
We are grateful to all our colleagues from the Virology Lab and the Cassava Program of CIAT. Special thanks to Dr. Amparo Rosero from Agrosavia and Dr. Diana Lopez-Alvarez from Universidad Nacional de Colombia, Palmira, for supporting this work. This research was co-funded by the CGIAR Research Program on Roots, Tubers, and Bananas (CRP-RTB) (https://www.cgiar.org/funders).
Declarations
Conflict of interest
The authors declare no conflict of interest.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.
Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.
Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.
Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
